RE:RE:ONCY's net operating loss carryforward a/o March 31, 2022Alternatively, a new approach to financing could become available to pre-revenue biotech companies if Congress signs off on a plan to give small biotech companies the ability to sell their net operating losses (NOLs) on the open market without actually going through the M&A process.
This plan would allow early-stage companies with an entirely new source of capital, without having to look towards venture capitalists and would serve as a catalyst for investors to return to supporting these early-stage companies to drive the development of new therapies, diagnostics and medical devices.
https://www.bizjournals.com/sanfrancisco/news/2022/06/14/net-operating-losses-nol-tax-credit-biotech.html